Secondary navigation: People section
1 / 2
Centre for the Study of Drug Development
Tufts University School of Medicine
75 Kneeland Street, 11th Floor
Boston, MA 02111
Dr. Christopher Milne joined the Center for the Study of Drug Development at the Tufts University School of Medicine (Tufts CSDD) in 1998 as a Senior Research Fellow and has published over 70 book chapters, white papers, and journal articles.
Currently, his research interests include: academic-industry collaborations; disease, demographic and market access factors in the emerging markets; incentive programs for pediatric studies, orphan products, neglected diseases, breakthrough therapies, and medical countermeasures (MCMs); and, tracking the progress of new regulatory and research initiatives such as regulatory science, translational medicine, personalized medicine, and FDA User Fee programs.
He is currently Director of Research at Tufts CSDD, Research Associate Professor at Tufts University Medical School, Innogen Center Associate (University of Edinburgh), as well as a member of the editorial boards of the Drug Information Associationâ€™s journal (TIRS) and Pharma Focus Asia.
Dr. Milne received a BA from Fordham University, an MPH from The Johns Hopkins University, and holds doctoral degrees in veterinary medicine and law, respectively from the UNPHU and UNH School of Law.
Milne, C-P, Mittra, J (2013) ‘Is Translational Medicine the Future of Therapy?’ in James Mittra and Christopher-Paul Milne (eds), ‘Translational Medicine:The Future of Therapy’, Pan Stanford Publishing
Milne, C-P, Tait, J (2009) ‘Evolution along the Government-Governance Continuum: Impacts of Regulations on Medicines Innovation in the United States’ in Lyall, C, Smith, J and Papaioannou, T (eds), ‘The Limits to Governance - The Challenge of Policy-Making for the New Life Sciences’, Ashgate Publishing Ltd, pp 107‑132